NASDAQ:PETX - Aratana Therapeutics Stock Price, News & Analysis

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

Aratana Therapeutics Inc (NASDAQ:PETX) posted its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company had revenue of $21.56 million for the quarter, compared to the consensus estimate of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative return on equity of 12.99%. View Aratana Therapeutics' Earnings History.

4 equities research analysts have issued 12-month price objectives for Aratana Therapeutics' stock. Their predictions range from $4.14 to $5.00. On average, they anticipate Aratana Therapeutics' share price to reach $4.7250 in the next year. This suggests that the stock has a possible downside of 4.0%. View Analyst Price Targets for Aratana Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aratana Therapeutics.

Headlines about PETX stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aratana Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Aratana Therapeutics.

Some companies that are related to Aratana Therapeutics include Cara Therapeutics (CARA), Y-mAbs Therapeutics (YMAB), Spectrum Pharmaceuticals (SPPI), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), Emisphere Technologies (EMIS), Homology Medicines (FIXX), ZIOPHARM Oncology (ZIOP), Amneal Pharmaceuticals (AMRX), Akero Therapeutics (AKRO), Principia Biopharma (PRNB), ANI Pharmaceuticals (ANIP), Arvinas (ARVN), Eagle Pharmaceuticals (EGRX) and Vanda Pharmaceuticals (VNDA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aratana Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Celldex Therapeutics (CLDX), ACADIA Pharmaceuticals (ACAD), Corcept Therapeutics (CORT), Exelixis (EXEL), BioDelivery Sciences International (BDSI), Aurinia Pharmaceuticals (AUPH), Pieris Pharmaceuticals (PIRS), Corbus Pharmaceuticals (CRBP) and Micron Technology (MU).

Aratana Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.63%), Man Group plc (5.58%), Alpine Associates Management Inc. (4.89%), Water Island Capital LLC (2.90%), Vanguard Group Inc. (2.74%) and OMERS ADMINISTRATION Corp (2.03%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, John C Ayres and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

PETX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, Bank of Montreal Can, State Board of Administration of Florida Retirement System and BNP Paribas Arbitrage SA. Company insiders that have sold Aratana Therapeutics company stock in the last year include Ernst Heinen, John C Ayres and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

PETX stock was purchased by a variety of institutional investors in the last quarter, including Man Group plc, Alpine Associates Management Inc., Water Island Capital LLC, OMERS ADMINISTRATION Corp, Gabelli Funds LLC, Polar Asset Management Partners Inc., GABELLI & Co INVESTMENT ADVISERS INC. and SG Americas Securities LLC. View Insider Buying and Selling for Aratana Therapeutics.

Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PETX stock can currently be purchased for approximately $4.92.

Aratana Therapeutics has a market capitalization of $241.08 million and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe.View Additional Information About Aratana Therapeutics.

The official website for Aratana Therapeutics is http://www.aratana.com/.

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]